The Market Dynamics of Generic Medicines in the Private Sector of 19 Low and Middle Income Countries between 2001 and 2011: A Descriptive Time Series Analysis

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Kaplan, Warren A ^a,b   Wirtz, Veronika J ^a,b   Stephens, Peter ^c,d  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b BOSTON UNIVERSITY   (United States)

^c IQVIA   (United States)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; NON PRESCRIPTION DRUG; PRESCRIPTION DRUG;

ARTICLE; ASIA; CONTROLLED STUDY; COST CONTROL; DESCRIPTIVE RESEARCH; DRUG COST; DRUG MARKETING; HEALTH CARE ORGANIZATION; HEALTH PROMOTION; HUMAN; LOWEST INCOME GROUP; MIDDLE EAST; MIDDLE INCOME GROUP; OBSERVATIONAL STUDY; SOCIOECONOMICS; SOUTH AFRICA; SOUTH AND CENTRAL AMERICA; TIME SERIES ANALYSIS; TREND STUDY; UNITED STATES;

DEVELOPING COUNTRIES; DRUG COSTS; DRUG SUBSTITUTION; DRUGS, GENERIC; HISTORY, 21ST CENTURY; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 84884737445     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074399     Document Type: Article

References (27)

1. Gomes Barra AC, Albuquerque I, (2011) A decade of generic pharmaceutical policies in Brazil. J. Generic Med 8: 72-75.
2. Sooksriwong C, Yoongthong W, Suwattanapreeda S, Chanjaruporn F, (2009) Medicine prices in Thailand: A result of no medicine pricing policy. Southern Med Rev 2: 10-14.
3. Kanavos P (2008) Generic policies: rhetoric vs. reality. European Observatory on Health Systems and Policies. Available: http://www.euro.who.int/_data/assets/pdf_file/0015/80340/EuroObserver_Summer_2008.pdf. Accessed 13 Dec 2012.
4. Sheppard A (2011) Generic Medicines: Essential contributors to the long-term health of society. IMS Health, London. Available: http://www.imshealth.com/imshealth/Global/Content/Document/Market_Measurement_TL/Generic_Medicines_GA.pdf. Accessed 4 Nov 2012.
5. Dylst P, Simoens S, (2010) Generic Medicine Pricing Policies in Europe: Current Status and Impact. Pharmaceuticals 3: 471-481.
6. Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585 (codified at 15 U.S.C. §§ 68b-68c, 70b (1994) (Hatch Waxman Act).
7. Generic Pharmaceutical Association (2005) GPhA Testimony before the House Energy and Commerce Committee on Generic Utilization. Available: http://www.gphaonline.org/resources/2009/02/12/gpha-testimony-house-energy-and-commerce-committee-generic-utilization. Accessed 10 Dec 2012.
8. Hamburg M (2012) Challenges and Opportunities for the Generic Drug Industry. Remarks at the GPhA Annual Meeting. Available: http://www.fda.gov/NewsEvents/Speeches/ucm294978.htm. Accessed 14 Dec 2012.
9. Kaplan WA, Ritz LS, Vitello M, Wirtz VJ, (2012) Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000-2010. Health Policy 106: 211-24.
10. Van Mourik MSM, Cameron A, Ewen M, Laing R (2010) Availability, price and affordability of cardiovascular medicines: A comparison across 36 countries using WHO/HAI data. BMC Cardiovasc. Disorders doi:-10.1186/1471-2261-10-25.
11. Cameron A, Mantel-Teeuwisse AK, Leufkens HG, Laing RO, (2012) Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved? Value Health 15: 664-73.
12. Waning B, Kaplan W, King A, Lawrence D, Leufkens H, Fox M, (2009) Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases. Bull World Health Organ 87: 520-528 doi: 10.2471/BLT.08.058925.
13. Waning BW, Diedrichsen E. Moon S (2010) A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries. J Int AIDS Soc 13: doi: -10.1186/1758-2652-13-35.
14. Waning B, Kyle M, Diedrichsen E, Soucy L, Hochstadt J, et al. (2010) Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets. Glob Health 6(9). Available: http://www.globalizationandhealth.com/content/6/1/9. Accessed 13 Dec 2012.
15. IMS Health. IMS Health Global Health Research Program. Available: http://www.imshealth.com/portal/site/ims/menuitem.edb2b81823f67dab41d84b903208c22a/?vgnextoid=388f35bb85ae3310VgnVCM100000ed152ca2RCRD&vgnextfmt=default. Accessed 14 Dec 2012.
16. World Bank, Washington DC (2012) Country and lending groups. Available: http://data.worldbank.org/about/country-classifications/country-and-lending-groups. Accessed 24 Nov 2012.
17. The Global Use of Medicines (2012): Outlook Through 2016 Report by the IMS Institute for Healthcare Informatics. Available: http://www.imshealth.com/deployedfiles/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/Global%20Use%20of%20Meds%202011/Medicines_Outlook_Through_2016_Report.pdf. Accessed 26 Jan 2013.
18. King D, Kanavos P, (2002) Encouraging the Use of Generic Medicines: Implications for Transition Economies. Croat Med J 43: 462-469.
19. Generic Pharmaceutical Association (2012) Savings: 1 Trillion over ten years. Generic drug savings in the U.S. (Fourth Annual Edition). Washington, D.C.: Generic Pharmaceutical Association. Available: http://www.gphaonline.org/media//cms/IMSStudyAug2012WEB.pdf. Accessed 8 Aug 2013.
20. U.S. Department of Health and Human Services (2010). ASPE Issue Brief. Expanding the use of generic drugs. Washington, D.C.: 2010. Available: http://aspe.hhs.gov/sp/reports/2010/genericdrugs/ib.shtml. Accessed 15 June 2013.
21. Singal GL, Nanda A, Kotwani A, (2011) A comparative evaluation of price and quality of some branded versus branded-generic medicines of the same manufacturer in India. Indian J Pharmacol 43: 131-136.
22. Madden JM, Meza E, Ewen M, Laing RO, Stephens P, et al. (2010) Measuring medicine prices in Peru: validation of key aspects of WHO/HAI survey methodology. Rev Panam Salud Publica 27: 291-299.
23. Dylst P, Simoens S, (2011) Does the Market Share of Generic Medicines Influence the Price Level? A European Analysis. Pharmacoecon 29: 875-882.
24. Pan American Health Organization (Organizacion Panamericana de Salud) (2010) Guide for the implementation of generic medicines strategies in Latin America and the Caribbean as a mechanism to improve access to medicines. Washington, DC: OPS. Available: htp://new.paho.org/hq/dmdocuments/2010/MT_OPSGenericos_consulta_102510.pdf. Accessed 4 May 2012.
25. Gonzalez Pier E, Barraza Llorens M (2011) Working for the Health of the Population. [Trabajando para la salud de la población: Trabajando por la salud de la población: Propuestas de política para el sector farmacéutico] Mexico, Funsalud. Available: http://www.funsalud.org.mx/eventos_2011/trabajando%20por%20la%20salud/Doc%20PolPublSFarm%20vFDigital%20060511.pdf. Accessed 13 Dec 2012.
26. Tobar F, (2008) Economía de los medicamentos genéricos en América Latina. Rev. Panam. Salud Pública 23: 59-67.
27. UNDP Patent Information and Transparency (2012) A Methodology for Patent Searches on Essential Medicines in Developing Countries. United Nations Development Programme, NY. Available: http://www.undp.org/content/dam/undp/library/hivaids/English/Patent%20Information%20and%20Transparency.pdf. Accessed 14 Dec 2012.